GBLI:NASDAQGlobal Indemnity Group, LLC Analysis
Data as of 2026-04-05 - not real-time
$27.55
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
Global Indemnity Group (GBLI) is trading at $27.55, barely above its calculated support of $26.91 and below the 20‑day SMA of 28.32, indicating limited upside in the near term. Technical indicators are bearish – the MACD histogram is negative, the 14‑day RSI sits at 43, and volume trends are decreasing, all pointing to continued pressure. However, the stock appears dramatically undervalued, with a DCF‑derived fair value of $360.73 and an upside potential of roughly 78%, while its forward PE of 8.35 is well below the industry average of 16.57. Fundamentally, GBLI delivers a solid dividend yield of 5.09% with an 80% payout ratio, a low beta of 0.24, and a price‑to‑book of 0.56, suggesting a value‑oriented profile. The latest earnings release highlighted improving underwriting performance – the combined ratio fell to 92.2% and Q4 underwriting profit rose to $11 million – yet Q4 EPS missed estimates (reported $0.41 vs. $0.89 expected), introducing short‑term earnings volatility. Cash generation is strong, with free cash flow of $270 million dwarfing dividend obligations, and the balance sheet shows modest debt ($8.3 million) relative to equity. Overall, the stock trades at a discount to peers, offers attractive income, but faces bearish technical momentum and liquidity constraints.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bearish technical indicators and price near support
- Decreasing volume indicating limited short‑term buying interest
- High dividend yield provides some cushion
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Significant valuation gap (DCF fair value vs. market price)
- Improving underwriting profitability and strong cash flow
- Attractive dividend yield with sustainable payout
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Low beta and defensive sector positioning
- Long‑term cash generation capacity and modest debt load
- Potential for price re‑rating as market recognizes undervaluation
Key Metrics & Analysis
Financial Health
Revenue Growth7.90%
Profit Margin5.63%
P/E Ratio15.7
ROE3.63%
ROA1.21%
Debt/Equity1.18
P/B Ratio0.6
Op. Cash Flow$9.1M
Free Cash Flow$270.7M
Industry P/E16.6
Technical Analysis
TrendBearish
RSI43.0
Support$26.91
Resistance$30.00
MA 20$28.32
MA 50$28.40
MA 200$29.12
MACDBearish
VolumeDecreasing
Fear & Greed Index78.8
Valuation
Fair Value$360.73
Target Price$49.00
Upside/Downside77.86%
GradeUndervalued
TypeValue
Dividend Yield5.09%
Risk Assessment
Beta0.24
Volatility23.93%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.